Background Impaired contractility is a feature of heart failure with reduced ejection fraction.
We assessed the pharmacokinetics and effects on cardiac function and structure of the …

Background Many patients with heart failure remain symptomatic and have a poor prognosis
despite existing treatments. Decreases in myocardial contractility and shortening of …

Aims The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv
mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is being tested …

Background Decreased systolic function is central to the pathogenesis of heart failure in
millions of patients worldwide, but mechanism-related adverse effects restrict existing …

Background The selective cardiac myosin activator omecamtiv mecarbil has been shown to
improve cardiac function in patients with heart failure with a reduced ejection fraction. Its …

Background: Omecamtiv mecarbil (OM) is a selective cardiac myosin activator that increases
myocardial function in healthy volunteers and in patients with chronic heart failure …

A central factor in the pathogenesis of heart failure (HF) with reduced ejection fraction is the
initial decrease in systolic function. Prior attempts at increasing cardiac contractility with oral …

Decreased systolic function is a central factor in the pathogenesis of heart failure, yet there
are no safe medical therapies to improve cardiac function in patients. Currently available …

Importance Exercise limitation is a cardinal manifestation of heart failure with reduced
ejection fraction (HFrEF) but is not consistently improved by any of the current guideline …

Decreased cardiac contractility is a central feature of systolic heart failure and yet we have
no effective drugs to improve cardiac contractility. Existing drugs that increase cardiac …